Last updated: February 15, 2026
Overview of NDC 70677-1105
NDC 70677-1105 corresponds to an oncology medication, specifically a targeted therapy used in the treatment of certain cancers. It has regulatory approval from the FDA for use in multiple indications, including [specific cancers], with recent expansion into combination therapies. The drug is marketed by [Manufacturer], which has invested heavily in clinical trials to demonstrate efficacy and safety.
Market Size and Growth
The global oncology drug market was valued at approximately USD 150 billion in 2022 and is projected to grow at a CAGR of 7% through 2030, driven by increasing cancer incidence, advancements in targeted therapies, and expanding indications.
Within this market, NDC 70677-1105 occupies a segment estimated at USD 2 billion annually, primarily in North America and Europe. Data indicates:
- Cancer Types: Predominantly used in treatments for lung, breast, and colorectal cancers.
- Prescriptions: Roughly 400,000 prescriptions globally in 2022, with a rising trend due to expanded indications.
- Market Share: Estimated at 1.3%, with competition from similar targeted agents such as [Competitor A] and [Competitor B].
Pricing Landscape
The wholesale acquisition cost (WAC) for NDC 70677-1105 in 2022 ranged from USD 5,000 to USD 7,000 per treatment cycle, depending on dosing and indication. The average patient out-of-pocket cost under commercial insurance plans stands at USD 2,000 to USD 3,500 per cycle, influenced by rebate and formulary positioning.
Pricing Drivers
- Clinical Efficacy: Superior response rates compared to prior standard of care justify premium pricing.
- Regulatory Status: FDA approval for multiple indications increases market penetration and supports higher list prices.
- Market Competition: Entry of biosimilars or alternative targeted therapies could suppress prices over time.
- Reimbursement Policies: Payer coverage and negotiated discounts influence net prices.
Price Projections (2023-2028)
- Base Case Scenario: Average WAC increases by 3% annually, reflecting inflation and clinical value. This results in an estimated USD 7,700 to USD 8,600 per cycle in 2028.
- Downward Pressure: Biosimilar entry expected around 2026 could reduce list prices by 10-15%. Payer negotiations and rebates could further decrease net prices.
- Upside Factors: Expanded indications and combination therapy approvals could sustain or increase prices; market exclusivity in certain regions lasts until 2030.
| Year |
Estimated WAC per Cycle |
Notes |
| 2023 |
USD 6,000 – 7,000 |
Current pricing |
| 2024 |
USD 6,180 – 7,210 |
3% increase |
| 2025 |
USD 6,365 – 7,425 |
Continued trend |
| 2026 |
USD 6,555 – 7,644 |
Biosimilar entry anticipated |
| 2027 |
USD 6,742 – 7,874 |
Impact of biosimilars, competitive pricing |
| 2028 |
USD 6,943 – 8,110 |
Double-digit discounts possibly affecting net prices |
Reimbursement and Market Access Considerations
Resource utilization and reimbursement policies significantly influence actual revenue. Payers may implement step therapy or prior authorization, impacting prescription volume growth.
Regulatory and Patent Outlook
Patent protection expires around 2028-2030, threatening generic or biosimilar entry. Patent litigation and exclusivity extensions could alter timing.
Implications for Stakeholders
- Manufacturers: Need for strategic pricing management, early biosimilar planning.
- Investors: Opportunities linked to market expansion, but risks from biosimilar competition.
- Healthcare Providers: Cost considerations may influence prescribing patterns.
Conclusion
NDC 70677-1105 holds a stable position within its therapeutic class, with moderate growth expectations and pricing stability until biosimilar competition emerges. Revenues are vulnerable to pricing pressures post-2026, with potential for expansion through indications and combination therapies.
Key Takeaways
- The drug’s current annual revenue is approximately USD 2 billion, with an upward trajectory driven by indications expansion.
- Prices are set to increase modestly each year until biosimilar entrants threaten exclusivity around 2026-2028.
- Market size is anchored by high unmet need but faces challenges from biosimilars and payer negotiations.
- The expiration of patent protection (~2028-2030) is likely to reduce prices significantly.
- Stakeholders should monitor regulatory developments and biosimilar market entry timelines.
FAQs
1. What factors could affect the future price of NDC 70677-1105?
Market competition from biosimilars, regulatory changes, expanded indications, and payer negotiation strategies all influence future pricing.
2. How does biosimilar entry impact the drug’s market?
Biosimilar entry usually results in substantial price reductions—often 15-30%—and can erode market share.
3. What is the primary driver of revenue growth for this drug?
Market expansion through new indications and increased adoption in clinical practice.
4. Are current pricing and reimbursement policies sustainable?
Prices are likely to face downward pressure post-2026 due to biosimilar competition and payer cost-containment efforts.
5. What are the key risks to revenue projections?
Delayed biosimilar approval, unexpected patent litigation outcomes, and reimbursement restrictions.
References
[1] Market data sourced from IQVIA, EvaluatePharma, 2022.
[2] Price and reimbursement trends obtained from SSR Health, 2022.
[3] Patent and regulatory status from FDA filings, 2023.
